cagrilintide and retatrutide together vs for Weight Loss Metabolic Health Cagrilintide vs Retatrutide: Amylin vs

2000 Mar;100(5):52535

162,163 Retatrutide (LY-3437943), a novel triple agonist developed by Eli Lilly that targets GLP-1R, GIPR and GCGR, has shown potential in preliminary clinical data for providing excellent blood sugar control and significant weight reduction

The peptide community has accumulated substantial anecdotal experience, but anecdotes are not epidemiology

Oral GLP-1 receptor agonists are also in the development phase, with preliminary data showing efficacy similar to that of Semaglutide

Thats because neither its therapeutic potential nor its safety has been tested on people

Because BPC 157 is not FDA-approved for medical use, there is no standardized approved dose, schedule, or route of administration